|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | WC2031 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||
| 化学式 | C22H24N2O8.1/2C2H6O.HCl.1/2H2O |
||||||||||
| 分子量 | 512.94 | CAS No. | 24390-14-5 | ||||||||
| Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (194.95 mM) | ||||||||
| Water | 100 mg/mL (194.95 mM) | ||||||||||
| Ethanol | Insoluble | ||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||
| 製品説明 | Doxycycline Hyclate is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is also an inhibitor of matrix metallo-proteinases (MMP). |
|---|---|
| in vitro | Doxycycline hyclate 10% (DOXY) has significant toxicity effects on osteoblast cells compared to the control group with a mean cell viability of 84%. Doxycycline hyclate 10% (DOXY) results in a significantly higher alkaline phosphatase activity (approximately 56%) than the control in osteoblasts. Doxycycline hyclate 10% (DOXY) seems to slightly altered the morphology of the osteoblasts. [1] |
| in vivo | Doxycycline hyclate is an effective treatment for acute E. canis infection in dogs. [2] Doxycycline hyclate (5 mg/kg, orally) decreases the collagenase activity in corneas obtained from rabbits. Doxycycline hyclate (5 mg/kg, orally) promotes corneal reepithelialization in the rabbit alkali-burn model, a result, perhaps, of the drug's ability to inhibit excessive collagenase activity. [3] Doxycycline hyclate results in 43% of prophylaxis in orally treated mice, in contrast, the sustained-release doxycycline hyclate completely protects mice from infection and resultant pathology. [4] Doxycycline hyclate results in bioavailability of 70%, Cmin of 1 mg/L, Cmax of 2.3 mg/L and elimination half-life of 7 hours in calves with immature rumen function. [5] |
| 細胞アッセイ | 細胞株 | MEFs |
|---|---|---|
| 濃度 | 100 ng/ml | |
| 反応時間 | 12 h | |
| 実験の流れ | Cells were treated with various concentrations of drug. |
|
| 動物実験 | 動物モデル | Dutch belted rabbits |
| 投薬量 | 1.5 or 5 mg/kg | |
| 投与方法 | p.o. |
|
| The assembly of RAB22A/TMEM33/RTN4 initiates a secretory ER-phagy pathway [ Cell Discov, 2025, 11(1):41] | PubMed: 40301304 |
| The NSP5, ORF6 and NSP13 of SARS-CoV-2 Cooperate to Modulate Inflammatory Cell Death Activation [ Adv Sci (Weinh), 2025, 12(41):e03977] | PubMed: 40810650 |
| TAF1 is required for fetal but not adult hematopoiesis in mice [ Dev Cell, 2025, S1534-5807(25)00405-8] | PubMed: 40675153 |
| KSHV hijacks the antiviral kinase IKKε to initiate lytic replication [ PLoS Pathog, 2025, 21(1):e1012856] | PubMed: 39823515 |
| Manganese is a potent inducer of lysosomal activity that inhibits de novo HBV infection [ PLoS Pathog, 2025, 21(1):e1012800] | PubMed: 39746094 |
| DFFB suppresses interferon to enable cancer persister cell regrowth [ bioRxiv, 2025, 2025.08.15.670603] | PubMed: 40894800 |
| CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma [ Nat Commun, 2024, 15(1):10594] | PubMed: 39632829 |
| BMP suppresses Wnt signaling via the Bcl11b-regulated NuRD complex to maintain intestinal stem cells [ EMBO J, 2024, ] | PubMed: 39433900 |
| Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers [ Acta Pharmacol Sin, 2024, ] | PubMed: 39506063 |
| Swine RNF5 positively regulates the antiviral activity of IFITM1 by mediating the degradation of ABHD16A [ J Virol, 2024, e0127724.] | PubMed: 39601593 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。